{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:55:17Z","timestamp":1791521717537,"version":"4.3.4"},"reference-count":35,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"5","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2018,10,10]]},"DOI":"10.1167\/tvst.7.5.24","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T14:31:51Z","timestamp":1539700311000},"page":"24","source":"Crossref","is-referenced-by-count":26,"title":["Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease"],"prefix":"10.1167","volume":"7","author":[{"given":"Terry G.","family":"Coursey","sequence":"first","affiliation":[{"name":"EyeCRO, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Wassel","sequence":"additional","affiliation":[{"name":"EyeCRO, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Quiambao","sequence":"additional","affiliation":[{"name":"EyeCRO, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal A.","family":"Farjo","sequence":"additional","affiliation":[{"name":"EyeCRO, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"i2164-2591-7-5-24-b01","doi-asserted-by":"crossref","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15: 276\u2013283.","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"i2164-2591-7-5-24-b02","doi-asserted-by":"crossref","unstructured":"Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017; 15: 334\u2013365.","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"i2164-2591-7-5-24-b03","doi-asserted-by":"crossref","unstructured":"Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W . Utility assessment among patients with dry eye disease. Ophthalmology. 2003; 110: 1412\u20131419.","DOI":"10.1016\/S0161-6420(03)00462-7"},{"key":"i2164-2591-7-5-24-b04","doi-asserted-by":"crossref","unstructured":"Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017; 15: 404\u2013437.","DOI":"10.1016\/j.jtos.2017.05.002"},{"key":"i2164-2591-7-5-24-b05","doi-asserted-by":"crossref","unstructured":"Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006; 176: 3950\u20133957.","DOI":"10.4049\/jimmunol.176.7.3950"},{"key":"i2164-2591-7-5-24-b06","unstructured":"Subcommittee E. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5 (2): 75\u201392."},{"key":"i2164-2591-7-5-24-b07","doi-asserted-by":"crossref","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017; 15: 438\u2013510.","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"i2164-2591-7-5-24-b08","unstructured":"Coursey TG, de Paiva CS. Managing Sjogren's syndrome and non-Sjogren syndrome dry eye with anti-inflammatory therapy. Clin Ophthalmol. 2014; 8: 1447\u20131458."},{"key":"i2164-2591-7-5-24-b09","doi-asserted-by":"crossref","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017; 15: 575\u2013628.","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"i2164-2591-7-5-24-b10","doi-asserted-by":"crossref","unstructured":"Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009; 54: 321\u2013338.","DOI":"10.1016\/j.survophthal.2009.02.002"},{"key":"i2164-2591-7-5-24-b11","doi-asserted-by":"crossref","unstructured":"Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009; 28: 1091\u20131096.","DOI":"10.1097\/ICO.0b013e3181a16472"},{"key":"i2164-2591-7-5-24-b12","unstructured":"Farjo R, Downie LE, Korb D, et al. Eyedrop application of CLT-005, a Stat3 inhibitor, is efficacious in animal models of wet and dry age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013; 54: 1716\u20131716."},{"key":"i2164-2591-7-5-24-b13","unstructured":"Wassel D, Farjo R, Mondalek F. Development of fenofibrate eyedrop emulsions for targeted delivery into the eye. Invest Ophthalmol Vis Sci. 2014; 55: 4617\u20134617."},{"key":"i2164-2591-7-5-24-b14","doi-asserted-by":"crossref","unstructured":"Gore A, Attar M, Pujara C, Neervannan S. Ocular emulsions and dry eye: a case study of a non-biological complex drug product delivered to a complex organ to treat a complex disease. GaBI J. 2017; 6: 13\u201323.","DOI":"10.5639\/gabij.2017.0601.004"},{"key":"i2164-2591-7-5-24-b15","doi-asserted-by":"crossref","unstructured":"Gao Y, Min K, Zhang Y, Su J, Greenwood M, Gronert K . Female-specific downregulation of tissue polymorphonuclear neutrophils drives impaired regulatory T cell and amplified effector T cell responses in autoimmune dry eye disease. J Immunol. 2015; 195: 3086\u20133099.","DOI":"10.4049\/jimmunol.1500610"},{"key":"i2164-2591-7-5-24-b16","doi-asserted-by":"crossref","unstructured":"Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017; 5: 284\u2013333.","DOI":"10.1016\/j.jtos.2017.04.001"},{"key":"i2164-2591-7-5-24-b17","unstructured":"Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002; 43: 632\u2013638."},{"key":"i2164-2591-7-5-24-b18","doi-asserted-by":"crossref","unstructured":"Song XJ, Li DQ, Farley W, et al. Neurturin-deficient mice develop dry eye and keratoconjunctivitis Sicca. Invest Ophthalmol Vis Sci. 2003; 44: 4223\u20134229.","DOI":"10.1167\/iovs.02-1319"},{"key":"i2164-2591-7-5-24-b19","doi-asserted-by":"crossref","unstructured":"Dursun D, Wang M, Monroy D, et al. Experimentally induced dry eye produces ocular surface inflammation and epithelial disease. Adv Exp Med Biol. 2002; 506: 647\u2013655.","DOI":"10.1007\/978-1-4615-0717-8_91"},{"key":"i2164-2591-7-5-24-b20","doi-asserted-by":"crossref","unstructured":"Coursey TG, Bohat R, Barbosa FL, Pflugfelder SC, de Paiva CS. Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D\/RAE-1 and release of IFN-gamma in experimental dry eye. J Immunol. 2014; 193: 5264\u20135272.","DOI":"10.4049\/jimmunol.1400016"},{"key":"i2164-2591-7-5-24-b21","doi-asserted-by":"crossref","unstructured":"Coursey TG, Gandhi NB, Volpe EA, Pflugfelder SC, de Paiva CS. Chemokine receptors CCR6 and CXCR3 are necessary for CD4(+) T cell mediated ocular surface disease in experimental dry eye disease. PLoS One. 2013; 8: e78508,","DOI":"10.1371\/journal.pone.0078508"},{"key":"i2164-2591-7-5-24-b22","doi-asserted-by":"crossref","unstructured":"de Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009; 2: 243\u2013253.","DOI":"10.1038\/mi.2009.5"},{"key":"i2164-2591-7-5-24-b23","doi-asserted-by":"crossref","unstructured":"de Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006; 47: 2847\u20132856.","DOI":"10.1167\/iovs.05-1281"},{"key":"i2164-2591-7-5-24-b24","doi-asserted-by":"crossref","unstructured":"Coursey TG, Henriksson JT, Marcano DC, et al. Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release. 2015; 213: 168\u2013174.","DOI":"10.1016\/j.jconrel.2015.07.007"},{"key":"i2164-2591-7-5-24-b25","unstructured":"Food and Drug Administration. Restasis (cyclosporine) ophthalmic label. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050790s020lbl.pdf. Accessed March 15, 2018."},{"key":"i2164-2591-7-5-24-b26","doi-asserted-by":"crossref","unstructured":"Munger RJ. Veterinary ophthalmology in laboratory animal studies. Vet Ophthalmol. 2002; 5: 167\u2013175.","DOI":"10.1046\/j.1463-5224.2002.00243.x"},{"key":"i2164-2591-7-5-24-b27","doi-asserted-by":"crossref","unstructured":"Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005; 24: 80\u201385.","DOI":"10.1097\/01.ico.0000133994.22392.47"},{"key":"i2164-2591-7-5-24-b28","doi-asserted-by":"crossref","unstructured":"Zhang X, Chen W, de Paiva CS, et al. Interferon-gamma exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest Ophthalmol Vis Sci. 2011; 52: 6279\u20136285.","DOI":"10.1167\/iovs.10-7081"},{"key":"i2164-2591-7-5-24-b29","doi-asserted-by":"crossref","unstructured":"Zhang X, de Paiva CS, Su Z, Volpe EA, Li DQ, Pflugfelder SC . Topical interferon-gamma neutralization prevents conjunctival goblet cell loss in experimental murine dry eye. Exp Eye Res. 2014; 118: 117\u2013124.","DOI":"10.1016\/j.exer.2013.11.011"},{"key":"i2164-2591-7-5-24-b30","doi-asserted-by":"crossref","unstructured":"Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120: 330\u2013337.","DOI":"10.1001\/archopht.120.3.330"},{"key":"i2164-2591-7-5-24-b31","doi-asserted-by":"crossref","unstructured":"Pflugfelder SC, de Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008; 27: 64\u201369.","DOI":"10.1097\/ICO.0b013e318158f6dc"},{"key":"i2164-2591-7-5-24-b32","doi-asserted-by":"crossref","unstructured":"Coursey TG, Tukler Henriksson J, Barbosa FL, de Paiva CS, Pflugfelder SC. Interferon-gamma-induced unfolded protein response in conjunctival goblet cells as a cause of mucin deficiency in Sjogren syndrome. Am J Pathol. 2016; 186: 1547\u20131558.","DOI":"10.1016\/j.ajpath.2016.02.004"},{"key":"i2164-2591-7-5-24-b33","doi-asserted-by":"crossref","unstructured":"de Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-?. Invest Ophthalmol Vis Sci. 2007; 48: 2553\u20132560.","DOI":"10.1167\/iovs.07-0069"},{"key":"i2164-2591-7-5-24-b34","doi-asserted-by":"crossref","unstructured":"Khan W, Aldouby YH, Avramoff A, Domb AJ. Cyclosporin nanosphere formulation for ophthalmic administration. Int J Pharm 2012; 437: 275\u2013276.","DOI":"10.1016\/j.ijpharm.2012.08.016"},{"key":"i2164-2591-7-5-24-b35","doi-asserted-by":"crossref","unstructured":"Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002; 21: 15\u201334.","DOI":"10.1016\/S1350-9462(01)00017-9"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/tvst.arvojournals.org\/article.aspx?articleid=2706662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T18:22:59Z","timestamp":1572114179000},"score":1,"resource":{"primary":{"URL":"http:\/\/tvst.arvojournals.org\/article.aspx?doi=10.1167\/tvst.7.5.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9,4]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.7.5.24","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,10]]}}}